BioCentury
ARTICLE | Clinical News

ADX71149: Completed Phase II enrollment

November 4, 2013 8:00 AM UTC

Addex said Johnson & Johnson's Janssen Pharmaceuticals Inc. unit completed enrollment of 120 MDD patients with anxiety symptoms in a double-blind, placebo-controlled, international Phase IIa trial eva...